<DOC>
	<DOC>NCT00123201</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine with Aura</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Male or female subjects 18 to 65 years, inclusive, with clinically diagnosed migraine with or without aura based on International Headache Society criteria Subjects who experience migraine with prolonged aura; familiar hemiplegic migraine; migrainous infarction or basilar migraine; and those with greater than eight migraine attacks per month and/or greater than 14 migraine days per month.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>efficacy &amp; safety, migraine headache, placebo-controlled</keyword>
	<keyword>migraine headache with or without aura</keyword>
</DOC>